Molbio Diagnostics Targets ₹940 Crore in IPO for Expansion and Stake Sale

Molbio Diagnostics, a prominent player in the molecular diagnostics sector, is preparing to raise ₹940 crore through its upcoming initial public offering (IPO). The company aims to secure ₹200 crore via a fresh share issuance to bolster capital expenditure, while an additional ₹740 crore will be generated through an offer for sale, reducing the promoter group's stake from 46.6% to 43%.

Expanding Global Reach and Product Offerings

Founded in 2000, Molbio Diagnostics specializes in developing diagnostic solutions for both infectious and non-communicable diseases. The company operates six manufacturing plants in India and serves clients across more than 90 countries. Key customers include government health programs, diagnostic labs, hospitals, and international healthcare organizations.

A significant portion of Molbio's revenue, over 80%, is derived from government and international aid agencies. The company's flagship product, the 'Truenat' platform, is a portable diagnostic system that provides accurate test results within an hour, particularly suited for resource-limited settings. Molbio offers molecular testing solutions for over 30 diseases through 43 diagnostic assays.

Financial Performance and Market Position

Molbio has experienced substantial financial growth, with revenue from operations increasing by 31.5% annually to ₹1,445.7 crore between FY24 and FY26. Net profit grew by 40.2% during the same period, reaching ₹164.1 crore. The company's EBITDA saw a 33.2% rise to ₹328.2 crore, with the EBITDA margin improving to 22.6% in FY26.

The company’s top clients contribute over half of its revenue, indicating a concentration risk. Notably, 74% of Molbio's revenue stems from the sale of test kits, with tuberculosis diagnostic kits accounting for 70% of these sales.

Valuation and Investor Considerations

Molbio Diagnostics is seeking a price-earnings (P/E) multiple of up to 57, based on FY26 net profit and post-IPO equity. While the company lacks directly comparable listed peers in India, other healthcare diagnostic and medical device firms such as Poly Medicure, Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic Centre trade at P/E multiples between 54 and 81.

Investors with a high-risk appetite may find the IPO appealing, given the company's robust financial growth and strategic positioning in the global diagnostics market. However, the revenue concentration among top clients and dependency on government contracts could pose potential risks.